1103929-71-0

Upstream product

• 5202-89-1 4-chlorobenzenesulfonyl chloride 
• 4480-83-5 1,4-dioxane-2,6-dione 

Downstream Products

• 1103930-94-4 methyl 2-(2-(2-(3,5-bis(trifluoromethyl)phenylamino)-2-oxoethoxy)acetamido)-5-chlorobenzoate 
• 1103929-74-3 methyl 5-chloro-2-(2-(2-(4-(4-chlorophenyl)piperazin-1-yl)-2-oxoethoxy)acetamido)benzoate 
• 1103930-76-2 methyl 5-chloro-2-(2-(2-(2,6-diisopropylphenylamino)-2-oxoethoxy)acetamido)benzoate 
• 1103929-87-8 methyl 2-[({2-{4-[bis(4-fluorophenyl)methyl]piperazin-1-yl}-2-oxoethoxy}acetyl)amino]-5-chlorobenzoate 
• 1103929-84-5 tert-butyl 2-(2-(2-(4-chloro-2-(methoxycarbonyl)phenylamino)-2-oxoethoxy)acetamido)-5-methyl-4-phenylthiophene-3-carboxylate 
• 1190221-84-1 methyl 5-chloro-2-{[(2-oxo-2-{[4-(pyridin-4-yl)phenyl]amino}ethoxy)acetyl]amino}benzoate 
• 1190222-68-4 methyl 5-chloro-2-{[(2-{[3-(furan-3-yl)phenyl]amino}-2-oxoethoxy)acetyl]amino}benzoate 
• 1190222-46-8 methyl 5-chloro-2-{[(2-oxo-2-{[3-(1H-pyrrol-1-yl)phenyl]amino}ethoxy)acetyl]amino}benzoate 
• 1190221-33-0 5-chloro-2-([(2-oxo-2-([3-(1H-pyrrol-1-yl)phenyl]amino)ethoxy)acetyl]amino)benzoic acid sodium salt 
• 1190221-65-8 5-chloro-2-{[(2-{[3-(1,2-oxazol-3-yl)phenyl]amino}-2-oxoethoxy)acetyl]amino}benzoic acid 
• 1190223-17-6 methyl 5-chloro-2-{[(2-{[3-(1,2-oxazol-3-yl)phenyl]amino}-2-oxoethoxy)acetyl]amino}benzoate 
• 1190221-56-7 5-chloro-2-{[(2-{[3-(1,2-oxazol-5-yl)phenyl]amino}-2-oxoethoxy)acetyl]amino}benzoic acid 
• 1190223-06-3 methyl 5-chloro-2-{[(2-{[3-(1,3-oxazol-5-yl)phenyl]amino}-2-oxoethoxy)acetyl]amino}benzoate 
• 1190221-55-6 5-chloro-2-([(2-([3-(1,3-oxazol-5-yl)phenyl]amino)-2-oxoethoxy)acetyl]amino)benzoic acid 

Relevant academic research and scientific papers

INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1

The present invention relates to a novel compound having plasminogen activator inhibitor-1 (PAI-1) inhibitory activity, and a PAI-1 inhibitor comprising the compound as an active ingredient. The present invention further relates to a pharmaceutical compos

Structure-activity relationships of new N-acylanthranilic acid derivatives as plasminogen activator inhibitor-1 inhibitors

Novel anthranilic acid derivatives having substituted N-acyl side chains were designed and synthesized for evaluation as plasminogen activator inhibitor-1 (PAI-1) inhibitors. Compounds with a 4-diphenylmethyl-1-piperazinyl moiety on the acyl side chains in general exhibited potent in vitro PAI-1 inhibitory activity and good pharmacokinetic profiles after oral administration in rats. Compound 16f (TM5275) was identified as a promising candidate for further pharmacological evaluation.

PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR

The present invention relates to an inhibitor of plasminogen activator inhibitor-1. The present invention further relates to a pharmaceutical composition that has an inhibitory action on PAI-1 activity and is useful in the prevention and treatment of various diseases whose onset is associated with PAI-1 activity. Furthermore, the present invention relates to a novel compound having PAI-1 inhibitory activity represented by the following general formula (I), and a salt thereof. Each symbol is defined as those in the specification.